Cannabix Technologies Inc. (CSE: BLO, OTCID: BLOZF, Frankfurt: 8CT) has unveiled fresh video demonstrations showcasing its innovative Marijuana Breath Test (MBT) solution, marking a critical moment as the U.S. moves to reclassify cannabis to Schedule III under the Controlled Substances Act.
The Technology Behind the Solution
The MBT system represents a significant advancement in detecting recent cannabis use through non-invasive breath collection. Cannabix’s proprietary hardware—the Breath Collection Unit (BCU) and Breath Cartridge (BC)—work together to capture and preserve breath samples for gold-standard liquid chromatography-mass spectrometry (LC-MS) analysis. This approach enables rapid, accurate detection of delta-9 THC, the primary psychoactive compound in cannabis.
The newly launched demonstrations highlight how this technology functions in real-world applications, providing both workplace safety teams and law enforcement with straightforward tools for roadside and facility screening.
Behind Cannabix stands Omega Laboratories Inc., a forensic drug testing leader with over 25 years of industry experience. Omega holds multiple federal and international certifications and operates an advanced laboratory facility specializing in novel drug detection methodologies. This collaboration positions Cannabix to advance MBT commercialization across U.S. and Canadian markets.
Market Timing and Public Safety Implications
The recent U.S. executive order to accelerate cannabis reclassification underscores why accurate THC breath detection has become essential. As cannabis use continues to expand across states, employers and transportation authorities face growing demands for reliable testing solutions. Cannabix’s MBT addresses this gap by offering a practical alternative to traditional testing methods.
Beyond workplace safety, the technology supports law enforcement needs for effective roadside screening, helping establish objective markers of recent cannabis consumption when regulatory compliance and public safety intersect.
About Cannabix Technologies
Cannabix Technologies develops breath-based detection systems for cannabis and alcohol screening across workplace, law enforcement, and other institutional settings. The company also markets BreathLogix, an autonomous alcohol screening device designed for organizations prioritizing safety and monitoring protocols.
The video demonstrations are now available on Cannabix’s official platform, providing stakeholders with detailed visual insights into the MBT system’s capabilities and operational framework.
For additional information, contact Cannabix Technologies at info@cannabixtechnologies.com
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Cannabix Advances Cannabis Safety with New Breath Test Product Demonstrations Amid U.S. Policy Shift
Cannabix Technologies Inc. (CSE: BLO, OTCID: BLOZF, Frankfurt: 8CT) has unveiled fresh video demonstrations showcasing its innovative Marijuana Breath Test (MBT) solution, marking a critical moment as the U.S. moves to reclassify cannabis to Schedule III under the Controlled Substances Act.
The Technology Behind the Solution
The MBT system represents a significant advancement in detecting recent cannabis use through non-invasive breath collection. Cannabix’s proprietary hardware—the Breath Collection Unit (BCU) and Breath Cartridge (BC)—work together to capture and preserve breath samples for gold-standard liquid chromatography-mass spectrometry (LC-MS) analysis. This approach enables rapid, accurate detection of delta-9 THC, the primary psychoactive compound in cannabis.
The newly launched demonstrations highlight how this technology functions in real-world applications, providing both workplace safety teams and law enforcement with straightforward tools for roadside and facility screening.
Strategic Partnership Accelerates Commercialization
Behind Cannabix stands Omega Laboratories Inc., a forensic drug testing leader with over 25 years of industry experience. Omega holds multiple federal and international certifications and operates an advanced laboratory facility specializing in novel drug detection methodologies. This collaboration positions Cannabix to advance MBT commercialization across U.S. and Canadian markets.
Market Timing and Public Safety Implications
The recent U.S. executive order to accelerate cannabis reclassification underscores why accurate THC breath detection has become essential. As cannabis use continues to expand across states, employers and transportation authorities face growing demands for reliable testing solutions. Cannabix’s MBT addresses this gap by offering a practical alternative to traditional testing methods.
Beyond workplace safety, the technology supports law enforcement needs for effective roadside screening, helping establish objective markers of recent cannabis consumption when regulatory compliance and public safety intersect.
About Cannabix Technologies
Cannabix Technologies develops breath-based detection systems for cannabis and alcohol screening across workplace, law enforcement, and other institutional settings. The company also markets BreathLogix, an autonomous alcohol screening device designed for organizations prioritizing safety and monitoring protocols.
The video demonstrations are now available on Cannabix’s official platform, providing stakeholders with detailed visual insights into the MBT system’s capabilities and operational framework.
For additional information, contact Cannabix Technologies at info@cannabixtechnologies.com